W 54011
目录号 : GC17129A selective C5aR antagonist
Cas No.:405098-33-1
Sample solution is provided at 25 µL, 10mM.
W 54011 is a potent and orally active non-peptide C5a receptor antagonist with Ki value of 2.2 nM [1].
The complement C5a is a 74-amino acid peptide produced during complement activation processes. C5a plays an important role in mast cell degranulation, smooth muscle contraction, monocyte migration, blood vessel dilatation, increased vascular permeability at in?ammatory sites , and recruitment of immune cells [1][2].
W 54011 is a potent and orally active C5a receptor antagonist. W 54011 inhibited the binding of 125I-labeled C5a to human neutrophils with Ki value of 2.2 nM. In human neutrophils, W 54011 inhibited C5a-induced chemotaxis, intracellular Ca2+ mobilization, and generation of reactive super oxide species with IC50 values of 2.7, 3.1, and 1.6 nM, respectively. W 54011 was species specific and was able to inhibit C5a-induced intracellular Ca2+ mobilization in neutrophils of cynomolgus monkeys and gerbils but not mice, rats, guinea pigs, rabbits, and dogs [1]. In HMEC-1 endothelial cell line, W 54011 signi?cantly inhibited C5a-induced proliferation and cell cycle progression in a dose-dependent way. W 54011 also inhibited the proliferative effects of 10 nM C5a and dose-dependently inhibited the formation of ring-shaped structures induced by C5a [2].
In gerbils, oral administration of W-54011 (3-30 mg/kg) dose-dependently inhibited C5a-induced neutropenia [1].
References:
[1].Sumichika H, Sakata K, Sato N, et al. Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem. 2002 Dec 20;277(51):49403-7.
[2].Kurihara R, Yamaoka K, Sawamukai N, et al. C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflamm Res. 2010 Aug;59(8):659-66.
Cas No. | 405098-33-1 | SDF | |
化学名 | N-(4-(dimethylamino)benzyl)-N-(4-isopropylphenyl)-7-methoxy-1,2,3,4-tetrahydronaphthalene-1-carboxamide hydrochloride | ||
Canonical SMILES | CC(C1=CC=C(N(C(C2CCCC3=C2C=C(OC)C=C3)=O)CC4=CC=C(N(C)C)C=C4)C=C1)C.Cl | ||
分子式 | C30H37ClN2O2 | 分子量 | 493.08 |
溶解度 | DMF: 30 mg/mL,DMSO: 30 mg/mL,Ethanol: 3 mg/mL | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0281 mL | 10.1403 mL | 20.2807 mL |
5 mM | 0.4056 mL | 2.0281 mL | 4.0561 mL |
10 mM | 0.2028 mL | 1.014 mL | 2.0281 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet